hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06330181 id: SC220178 id: HT9425-23-1-1019 type: OTHER_GRANT domain: Department of Depense briefTitle: Virtual Walking Therapy for Neuropathic Pain Following Incomplete Spinal Cord Injury overallStatus: RECRUITING date: 2024-03 date: 2026-01 date: 2027-01 date: 2024-03-26 date: 2024-03-26 name: Texas A&M University class: OTHER name: United States Department of Defense name: Immersive Experience Labs briefSummary: The purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with incomplete spinal cord injury. conditions: Spinal Cord Injuries conditions: Neuropathic Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomly assigned to one of two intervention arms. Both groups receive the same number of sessions, duration of sessions, and measures procured. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: VR Game 1 name: VR Game 2 measure: Change in Pain Intensity measure: Change in Pain Quality measure: Change in Pain Interference measure: Post treatment change measure: Change in mood measure: Change in quality of life measure: Neurological changes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Texas A&M University status: RECRUITING city: College Station state: Texas zip: 77843 country: United States name: Amanda Higgins, M.E.d role: CONTACT phone: 804-569-5965 email: sci@vrwalk.org name: Zina Trost, PhD role: PRINCIPAL_INVESTIGATOR lat: 30.62798 lon: -96.33441 hasResults: False
nctId: NCT06330168 id: 36264PR573/2/24 briefTitle: Paravertebral Calcitonin in Thoracotomy overallStatus: RECRUITING date: 2024-03-28 date: 2025-04-10 date: 2025-04-10 date: 2024-03-26 date: 2024-03-28 name: Tanta University class: OTHER briefSummary: This prospective randomized double-blinded controlled study will be conducted to evaluate the effect of adding calcitonin to bupivacaine in thoracic paravertebral block for patients undergoing thoracotomy. conditions: Calcitonin conditions: Paravertebral conditions: Thoracotomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: triple whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: bupivacaine-calcitonin-fentanyl name: Bupivacaine-fentanyl measure: morphine consumption measure: numerical rating scale scores measure: incidence of chronic pain measure: Side effects sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tanta University Hospitals status: RECRUITING city: Tanta state: Gharbiya zip: 31527 country: Egypt name: Osama M Rehab, MD role: CONTACT phone: 01095210806 email: osamarehab@med.tanta.edu.eg lat: 30.78847 lon: 31.00192 hasResults: False
nctId: NCT06330155 id: 2024-01-032 briefTitle: A Genetic Study for Alzheimer Dementia: Case-control Study overallStatus: NOT_YET_RECRUITING date: 2024-03-26 date: 2026-12-31 date: 2026-12-31 date: 2024-03-26 date: 2024-04-04 name: MinYoung Kim, MD, PhD class: OTHER briefSummary: The purpose of this study is to find out the difference in genetic test results between Alzheimer's dementia patients and healthy subjects.
The investigators want to identify genes that are importantly related to Alzheimer's dementia. conditions: Alzheimer Dementia (AD) studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 20 type: ESTIMATED measure: genetic analysis measure: Measurement of Korean version of mini-mental state examination (K-MMSE) measure: Measurement of Clinical Dementia Rating (CDR) measure: Measurement of Geriatric Depression Scale (GDSd) sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330142 id: 2022-006 briefTitle: Hippotherapy Teenager-pediatric Radiotherapy acronym: T-QAP overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-15 date: 2025-12-15 date: 2024-03-26 date: 2024-03-26 name: Institut de cancérologie Strasbourg Europe class: OTHER briefSummary: This study proposes a horse-assisted therapy (HAT) approach to accompany children and young adults undergoing irradiation in the ICANS Radiotherapy Department.
The aim of this new approach is to improve quality of life and reduce anxiety in children and adolescents treated with radiotherapy. The impact of equine-assisted therapy on quality of life and anxiety disorders will be described prospectively between the start and end of irradiation in children and parents who agree to inclusion. conditions: Radiotherapy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 22 type: ESTIMATED name: Participation in 10 horse-assisted therapy sessions measure: Evolution of quality of life between the beginning and the end of horse-assisted therapy (HAT) in children (self-questionnaire) treated with radiotherapy measure: Improving children's quality of life between the start and end of irradiation (hetero-questionnaire) by HAT measure: Decrease anxiety disorders between the beginning - child version and end of irradiation in children (self-questionnaire) with HAT measure: Decrease anxiety disorders between the beginning - parents' version and end of irradiation in children (self-questionnaire) with HAT measure: Assessing the acute side effects of radiotherapy at the start and end of irradiation measure: Study the relevance of the various equestrian activities proposed as a strategy for improving care through the horse measure: Evaluate participant's expectations and satisfaction with their care measure: Assess the medical electroradiology technician's (MERT's) impression of the child's well-being during irradiation measure: Assessing the impact of HAT on the child during irradiation according to the MERT measure: Evaluate the rider's impression of the child's well-being of the child during HAT sessions measure: Assessing the impact of an alternative activity on parents' satisfaction with care sex: ALL minimumAge: 8 Years maximumAge: 17 Years stdAges: CHILD facility: Institut de Cancerologie Strasbourg Europe city: Strasbourg zip: 67033 country: France name: Valérie SARTORI role: CONTACT phone: 0368767223 email: v.sartori@icans.eu name: Manon VOEGELIN role: CONTACT phone: 0368767360 email: promotion-rc@icans.eu name: Laura BOINOT-FRITSCH role: PRINCIPAL_INVESTIGATOR name: Georges NOEL role: SUB_INVESTIGATOR name: Claire DOSSUN role: SUB_INVESTIGATOR lat: 48.58392 lon: 7.74553 hasResults: False
nctId: NCT06330129 id: Pegasus01_Val briefTitle: Validity and Reliability of Trunk Strength Device acronym: PEGASUS overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-03-31 date: 2025-12-31 date: 2024-03-26 date: 2024-03-26 name: Schulthess Klinik class: OTHER name: Balgrist Campus AG briefSummary: The study aims to evaluate the accuracy and consistency of assessing trunk muscle strength using an isometric device (Pegasus, Leipzig, Germany). Thirty healthy volunteers will undergo maximal isometric strength testing with the device, repeated one week later to assess repeatability. Surface electrodes will measure muscle activation, while MRI scans will assess structural condition. conditions: Trunk Muscle Strength studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 30 type: ESTIMATED name: CTT Pegasus measure: maximal isometric trunk muscle strength measure: MRI muscle morphology measure: Electromyography (EMG) activity sex: ALL minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT hasResults: False
nctId: NCT06330116 id: 2023-05348-01 briefTitle: Different Forms of OMT as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea acronym: SNORT overallStatus: ENROLLING_BY_INVITATION date: 2024-03-29 date: 2025-03-28 date: 2025-03-28 date: 2024-03-26 date: 2024-03-26 name: Region Västerbotten class: OTHER_GOV name: Interreg name: Umeå University briefSummary: Objective the present project aims to assess the impact of 1) oral screen training, group training, and the use of neuromuscular electrical training (NMES) as orofacial myofunctional therapy (OMT) methods for reducing the apnea-hypopnea index (AHI) among adults with mild to moderate sleep apnea and 2) if these different training methods can reduce snoring and affect the level of sleepiness and quality of life. Study design The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase, and follow-up measurements.
Methods 141 consecutive adult subjects, 71 men and 70 women referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sites, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the three different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Participants in Umeå will be randomized to either training with IQoro or serving as controls. Participants in Köge will be randomized to either training with Exciteosa, group training, or controls.
The secondary outcomes are change in snoring frequency, sound level dB (A) according to a questionnaire, the Basic Nordic Sleep Questionnaire (BNSQ), daytime sleepiness using the Epworth Sleepiness Scale (ESS), change in quality of life using the short form -36 (SF-36) and muscle strength in tongue before and after treatment. conditions: Sleep Apnea, Obstructive conditions: Snoring studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 141 consecutive adult subjects, 71 men and 70 women, referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sights, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the 3 different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Patients in Umeå will be randomized to either training with IQoro or serving as controls. Patients in Köge will be randomized to either training with Exciteosa group training, or controls. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase and follow-up measurements, and controls without intervention. The results are then analyzed and blinded to the evaluators. whoMasked: OUTCOMES_ASSESSOR count: 141 type: ESTIMATED name: IQoro name: eXciteosa name: Grouptraining measure: Apnea-hyponpnea index (AHI) measure: Questionnaries measure: Snoring measure: Tounge strenght sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zealand University Hospital city: Köge state: Sjaelland zip: 4600 country: Denmark lat: 55.45802 lon: 12.18214 facility: Skåne University Hospital city: Lund state: Skåne zip: 22100 country: Sweden lat: 55.70584 lon: 13.19321 facility: Region Västerbotten city: Umeå state: Västerbotten zip: 901 85 country: Sweden lat: 63.82842 lon: 20.25972 hasResults: False
nctId: NCT06330103 id: RayongH briefTitle: Efficacy of AI EF Screening by Using Smartphone Application Recorded PLAX View Cardiac Ultrasound Video Clips overallStatus: COMPLETED date: 2023-05-01 date: 2023-07-31 date: 2023-07-31 date: 2024-03-26 date: 2024-03-26 name: Rayong Hospital class: OTHER name: Chulalongkorn University briefSummary: Assessing the Efficacy of Artificial Intelligence in Left Ventricular Function Screening Using Parasternal Long Axis View Cardiac Ultrasound Video Clips
ABSTRACT BACKGROUND: Echocardiography serves as a fundamental diagnostic procedure for managing heart failure patients. Data from Thailand's Ministry of Public Health reveals that there is a substantial patient population, with over 100,000 admissions annually due to this condition. Nevertheless, the widespread implementation of echocardiography in this patient group remains challenging, primarily due to limitations in specialist resources, particularly in rural community hospitals. Although modern community hospitals are equipped with ultrasound machines capable of basic cardiac assessment (e.g., parasternal long axis view), the demand for expert cardiologists remains a formidable obstacle to achieving comprehensive diagnostic capabilities. Leveraging the capabilities of Artificial Intelligence (AI) technology, proficient in the accurate prediction and processing of diverse healthcare data types, offers a promising for addressing this prevailing issue. This study is designed to assess the effectiveness of AI in evaluating cardiac performance from parasternal long axis view ultrasound video clips obtained via the smartphone application.
OBJECTIVES: To evaluate the effectiveness of artificial intelligence in screening cardiac function from parasternal long axis view cardiac ultrasound video clips obtained through the smartphone application. conditions: Heart Failure conditions: Heart Failure With Reduced Ejection Fraction conditions: Cardiac Failure conditions: Echocardiography conditions: Artificial Intelligence studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 923 samples that were evaluated for LVEF by certified cardiologists, 739 clips were used to train AI, while the remaining 184 clips were used to test if AI could process the results correctly. Artificial intelligence aims to classify cardiac function into three groups: Reduced EF, Mildly Reduced EF, and Preserved LV. primaryPurpose: DIAGNOSTIC masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 923 type: ACTUAL name: Easy EF measure: efficiency of AI in screening left ventricular cardiac function by use smartphone application sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Rayong Hospital city: Rayong zip: 066 country: Thailand lat: 12.68095 lon: 101.25798 hasResults: False
nctId: NCT06330090 id: NL84688.091.23 id: 101040534 type: OTHER_GRANT domain: European Research Council briefTitle: COgnitive Dynamics in Early Childhood acronym: CODEC overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2027-12 date: 2027-12 date: 2024-03-26 date: 2024-03-26 name: Radboud University Medical Center class: OTHER briefSummary: The goal of this accelerated longitudinal observational cohort study is to advance our understanding of cognitive variability in children aged 7 to 10 at first measurement. The CODEC study aims to integrate experience sampling methods, longitudinal designs, deep phenotyping cohorts, and state-of-the-art statistical methodologies to investigate three core questions:
3. What are the long-term consequences and outcomes associated with differences in cognitive variability? conditions: Cognitive Change studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED measure: Reaction times from the vocabulary cognitive task measure: Reaction times from the exploration cognitive task measure: Reaction times from the Working Memory cognitive task measure: Reaction times from the speed cognitive task measure: Reaction times from the fluid reasoning cognitive task measure: Mood score on smiley slider measure: Sleep score on smiley slider measure: MP-RAGE MRI sequence baseline measure: Functional MRI sequence of low time constraint reasoning task at baseline measure: gaze direction during reasoning task at baseline measure: pupil dilation during reasoning task at baseline measure: Naturalistic viewing fMRI at baseline measure: Naturalistic viewing fMRI at follow-up measure: Functional MRI sequence of high time constraint reasoning task at follow-up measure: gaze direction during reasoning task at baseline at follow-up measure: pupil dilation during reasoning task at baseline at follow-up measure: Functional MRI sequence of low time constraint reasoning task at follow-up measure: Sparse MP2-Rage MRI sequence baseline measure: Diffusion weighted imaging MRI sequence baseline measure: MP-RAGE MRI sequence follow up measure: Sparse MP2-Rage MRI sequence follow up measure: Diffusion weighted imaging MRI sequence follow up measure: Total score for Highly Sensitive Child scale at baseline measure: Total score for Strengths and difficulties questionnaire at baseline measure: Total score for BRIEF-2 questionnaire at baseline measure: Total score for BRIEF-2 questionnaire at follow-up measure: Total score for Strengths and difficulties questionnaire at follow-up measure: Total score for Mind Excessively Wandering Scale scale at baseline measure: Originality score for the Alternative Uses Tasks at baseline measure: Originality score for the Alternative Uses Tasks at follow-up measure: Total score for Parent-reported Mind Excessively Wandering Scale scale at baseline measure: Total score for Parent-reported Socio-demographic questionnaire at baseline measure: Total score for Parent-reported Socio-demographic questionnaire at follow-up measure: Total score for Mind Excessively Wandering Scale scale at follow-up measure: Total score for Parent-reported Mind Excessively Wandering Scale scale at follow-up measure: Total score for Highly Sensitive Child scale at follow-up measure: motivation rating for cognitive tasks measure: Decibel of background noise during cognitive testing measure: Academic school result baseline measure: Academic school result follow-up measure: Parent reaction times on cognitive battery at baseline measure: Parent reaction times on cognitive battery at follow-up sex: ALL minimumAge: 7 Years maximumAge: 13 Years stdAges: CHILD hasResults: False
nctId: NCT06330077 id: APHP200027 id: 2021-003584-99 type: EUDRACT_NUMBER briefTitle: Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis acronym: MODIF-MS overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2027-03 date: 2027-06 date: 2024-03-26 date: 2024-03-26 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Multiple sclerosis (MS) is the most frequently acquired demyelinating disease and the first cause of non-traumatic chronic disability in young adults. Major progress has been achieved in the treatment of MS through the development of therapies targeting the adaptative immune system, which drastically reduce the relapse rate, with various efficiency and safety profiles (Ontaneda, 2015). However, these drugs generally fail to prevent disability worsening along the disease course, and we are now assisting to a shift in therapeutic objectives from the development of new immune drugs towards the identification of therapeutic strategies that could prevent neurodegeneration by promoting myelin regeneration (Stangel, 2017; Stankoff, 2016), in order to prevent neurological disability in MS (Irvine and Blakemore, 2008; Patrikios, 2006; Duncan I, 2017, Bodini, 2016).
Among the first candidate compounds developed to promote remyelination was the anti Lingo1 antibody, which enhance remyelination (Mi, 2009). Medium and large throughput screening of drug libraries subsequently identified several chemical classes of compounds with strong promyelinating properties, such as the antifongic drug miconazole (Najm, 2015) or the muscarinic antagonist clemastine (Wei, 2014). A recent innovative trial has investigated the effect of clemastine, compared to placebo, in a small sample of subjects (25 patients per group) and showed that clemastine could significantly improve the optic nerve conduction speed which reflecting myelin integrity and functionality (Green, 2017).
Our preclinical research has allowed us to identify ifenprodil as a powerful drug to promote myelin repair in vitro and in vivo across species. In parallel our team recently pioneered and optimized a PET imaging approach for quantifying remyelination in the whole brain, that allowed to enhance the sensitivity to detect the myelin repair process, and showed that patients are characterized by heterogeneous profiles of spontaneous remyelination profiles that are closely linked to disability accrual (Bodini, 2016). conditions: Multiple Sclerosis conditions: Remitting Relapsing Multiple Sclerosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Ifenprodil name: Placebo measure: Change in P100 latency according to visual evoked potential. measure: Proportion of voxels within white matter lesions classified as remyelinating measure: Proportion of remyelinating voxels extracted in cortical regions from magnetization transfer imaging (MTR) acquisitions measure: Change in amplitude of P100 on to visual evoked potential measure: Change in retinal nerve fibre layer (RNFL) and ganglion cell complex (GCC) thickness on OCT measure: Change in blood concentration of NfL fragments measure: Change in the brain atrophy rate measure: The correlation between the change in the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions measure: The comparison of the proportion of remyelinating voxels extracted in white matter lesions from [18F]florbetaben PET acquisitions measure: Incidence of adverse drug reactions sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Hôpital Neurologique Pierre WERTHEIMER - HCL city: Bron zip: 69677 country: France name: Françoise DURAND DUBIEF, MD role: CONTACT phone: 04 72 35 75 22 email: françoise.durand-dubief@chu-lyon.fr lat: 45.73333 lon: 4.91667 facility: Groupe Hospitalier Pitié Salpêtrière - APHP city: Paris zip: 75013 country: France name: Bruno STANKOFF, MD role: CONTACT email: bruno.stankoff@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False